RxDoctor Payments Data

Cesar Palana, MD

Internal Medicine · Los Angeles, CANPI 1467712604

Payments from drug & device makers

$37,203in general payments, 2019–2025

Across 30 payments — averaging $1240.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$37K
  • Johnson & Johnson$121
  • Sanofi-aventis U.S. LLC$104
  • Gilead$66
  • Bayer$55
  • Agios Pharmaceuticals, Inc.$33
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$37,203 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$357,110
Medicare patients
310
Services billed
3,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban341$110,234
JardianceEmpagliflozin310$95,522
JanuviaSitagliptin Phosphate115$39,982
SantylCollagenase Clostridium Hist.48$33,174
OzempicSemaglutide32$32,538
XifaxanRifaximin16$21,973
EntrestoSacubitril/Valsartan66$20,174
Atorvastatin Calcium1,216$19,692
Levetiracetam275$16,760
Divalproex Sodium188$13,277
RenvelaSevelamer Carbonate14$12,657
XareltoRivaroxaban33$12,354
Memantine Hcl177$10,288
Pantoprazole Sodium218$10,213
Incruse ElliptaUmeclidinium Bromide22$8,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$17$20,17466 claims
Sanofi-aventis U.S. LLCRenvela, Lantus$104$18,31591 claims
Johnson & JohnsonXarelto, Invokana$121$17,92852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →